5-HT3 antagonist (intravenous)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for 5-HT3 antagonist (intravenous), covering 2023-05-03 to 2023-05-03. Get the full timeline:
Most recent: Clinical Trial Update: Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer [Phase 4]